Prime Medicine, Inc. (PRME) Tops Q2 EPS by 3c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.46), $0.03 better than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges
• Career Education (CECO) Tops Q2 EPS by 20c ; Offers Guidance
• MoonLake Immunotherapeutics (MLTX) Tops Q2 EPS by 9c